Xiangbing Meng

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. pmc Drug resistance mediated by AEG-1/MTDH/LYRIC
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, USA
    Adv Cancer Res 120:135-57. 2013
  2. pmc Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
    Xiangbing Meng
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA
    Gynecol Oncol 128:461-9. 2013
  3. pmc Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa 52242, USA
    J Biol Chem 287:4485-91. 2012
  4. pmc Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e20920. 2011
  5. pmc Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells
    Shujie Yang
    200 Hawkins Drive, University of Iowa, Iowa City, IA 52242
    Curr Pharm Des 20:1874-80. 2014
  6. pmc Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers
    Henry D Reyes
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA
    Mol Diagn Ther 18:137-51. 2014
  7. pmc A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
    Shujie Yang
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e26343. 2011

Collaborators

Detail Information

Publications7

  1. pmc Drug resistance mediated by AEG-1/MTDH/LYRIC
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, USA
    Adv Cancer Res 120:135-57. 2013
    ..The multiple functions of AEG-1/MTDH/LYRIC in drug resistance highlight that it is a viable target as an anticancer agent for a wide variety of cancers. ..
  2. pmc Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
    Xiangbing Meng
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA
    Gynecol Oncol 128:461-9. 2013
    ....
  3. pmc Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa 52242, USA
    J Biol Chem 287:4485-91. 2012
    ..Taken together, our data identify a novel function for cytoplasmic MTDH as an RNA-binding protein. Our findings implicate cytoplasmic MTDH in cell survival and broad drug resistance via association with RNA and RNA-binding proteins...
  4. pmc Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment
    Xiangbing Meng
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e20920. 2011
    ..These findings indicate that targeting or depleting MTDH is a potentially novel avenue for reversing therapeutic resistance in patients with endometrial cancer...
  5. pmc Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells
    Shujie Yang
    200 Hawkins Drive, University of Iowa, Iowa City, IA 52242
    Curr Pharm Des 20:1874-80. 2014
    ....
  6. pmc Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers
    Henry D Reyes
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, 52242, USA
    Mol Diagn Ther 18:137-51. 2014
    ..In this review, we describe the existing evidence for the use of HER family members as diagnostic and prognostic indicators as well as their potential as therapeutic targets in gynecologic cancers. ..
  7. pmc A mechanism for synergy with combined mTOR and PI3 kinase inhibitors
    Shujie Yang
    Department of Obstetrics and Gynecology, The University of Iowa, Iowa City, Iowa, United States of America
    PLoS ONE 6:e26343. 2011
    ..We conclude that the addition of a PI3K inhibitor overcomes cellular resistance to mTORC1 inhibitors regardless of PTEN status, and thus substantially expands the molecular phenotype of tumors likely to respond...